Nektar Therapeutics (NKTR)
(Real Time Quote from BATS)
$1.30 USD
+0.07 (5.69%)
Updated Jul 10, 2024 01:34 PM ET
3-Hold of 5 3
D Value D Growth C Momentum D VGM
Earnings News For NKTR
-
Nektar's (NKTR) Q1 Earnings and Revenues Surpass Estimates
-
Nektar: Q1 Earnings Snapshot
-
Nektar Therapeutics Reports First Quarter 2024 Financial Results
-
Nektar (NKTR) Up 7.5% Since Last Earnings Report: Can It Continue?
-
Nektar (NKTR) Q4 Loss Wider Than Expected, Revenue Beat
-
Nektar: Q4 Earnings Snapshot
-
Nektar Therapeutics (NKTR) Reports Q4 Loss, Tops Revenue Estimates
-
Nektar Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results
-
Will Nektar Therapeutics (NKTR) Report Negative Q4 Earnings? What You Should Know
-
Nektar (NKTR) Up 4% Since Last Earnings Report: Can It Continue?
-
Nektar Therapeutics (NKTR) Incurs Wider-Than-Expected Q3 Loss
-
Nektar: Q3 Earnings Snapshot
-
Nektar Therapeutics Reports Third Quarter 2023 Financial Results
-
Nektar Therapeutics (NKTR) Expected to Beat Earnings Estimates: Should You Buy?
-
Why Is Nektar (NKTR) Down 37.1% Since Last Earnings Report?
-
Nektar Therapeutics (NKTR) Q2 Loss Narrows, Sales Miss
-
Nektar Therapeutics (NKTR) Reports Q2 Loss, Lags Revenue Estimates
-
Nektar: Q2 Earnings Snapshot
-
Nektar Therapeutics Reports Second Quarter 2023 Financial Results
-
Why Is Nektar (NKTR) Down 19.7% Since Last Earnings Report?
-
Nektar Therapeutics (NKTR) Reports Q1 Loss, Tops Revenue Estimates
-
Nektar: Q1 Earnings Snapshot
-
Nektar Therapeutics Reports First Quarter 2023 Financial Results
-
Will Nektar Therapeutics (NKTR) Report Negative Earnings Next Week? What You Should Know
-
Why Is Nektar (NKTR) Down 51.9% Since Last Earnings Report?